NIAGEN BIOSCIENCE, INC. (NAGE) Spending and interest coverage
- R&D / revenue · 12 months: Value 5.03%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 5.38%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 5.03% | Research and development expense / revenue. Period ending 2026-06-30. $6.50M ÷ $129.08M × 100 ≈ 5.03% |
| Stock-based compensation / revenue · 12 months | 5.38% | Share-based compensation / revenue. Period ending 2026-06-30. $6.94M ÷ $129.08M × 100 ≈ 5.38% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 6.50M USD | Research and Development Expense |
| Revenue | 129.08M USD | |
| Stock-based compensation | 6.94M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 10.60M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $6.50M | $129.08M | $6.94M | $10.60M | (m) | 5.03% | 5.38% | (m) | (m) |
| 2026-03-31 | $6.55M | $130.42M | $6.71M | $13.08M | (m) | 5.02% | 5.14% | (m) | (m) |
| 2025-12-31 | $6.33M | $129.42M | $6.07M | $16.28M | (m) | 4.89% | 4.69% | (m) | (m) |
| 2025-09-30 | $5.93M | $124.71M | $5.07M | $19.30M | (m) | 4.76% | 4.07% | (m) | (m) |
| 2025-06-30 | $5.43M | $116.30M | $4.05M | $16.67M | (m) | 4.67% | 3.48% | (m) | (m) |
| 2025-03-31 | $5.18M | $107.92M | $3.75M | $13.23M | (m) | 4.80% | 3.47% | (m) | (m) |
| 2024-12-31 | $6.02M | $99.60M | $3.66M | $7.73M | (m) | 6.04% | 3.67% | (m) | (m) |
| 2024-09-30 | $5.86M | $91.67M | $3.94M | $447.00K | (m) | 6.39% | 4.30% | (m) | (m) |
| 2024-06-30 | $5.81M | $85.58M | $4.32M | $-2.30M | (m) | 6.79% | 5.05% | (m) | (m) |
| 2024-03-31 | $5.86M | $83.17M | $4.46M | $-4.36M | (m) | 7.05% | 5.37% | (m) | (m) |
| 2023-12-31 | $4.96M | $83.57M | $4.75M | $-5.60M | (m) | 5.93% | 5.69% | (m) | (m) |
| 2023-09-30 | $5.08M | $83.37M | $5.04M | $-6.88M | (m) | 6.09% | 6.05% | (m) | (m) |
| 2023-06-30 | $5.06M | $80.94M | $5.15M | $-8.79M | (m) | 6.25% | 6.37% | (m) | (m) |
| 2023-03-31 | $4.94M | $77.35M | $5.12M | $-12.86M | (m) | 6.39% | 6.62% | (m) | (m) |
| 2022-12-31 | $4.83M | $72.05M | $5.74M | $-18.63M | (m) | 6.70% | 7.97% | (m) | (m) |
| 2022-09-30 | $4.59M | $68.81M | $5.89M | $-22.50M | $32.00K | 6.67% | 8.55% | -703.13× | Reported |
| 2022-06-30 | $4.36M | $69.06M | $6.48M | $-28.28M | $42.00K | 6.32% | 9.38% | -673.24× | Reported |
| 2022-03-31 | $4.12M | $70.03M | $6.80M | $-27.44M | $44.00K | 5.89% | 9.71% | -623.70× | Reported |
| 2021-12-31 | $3.83M | $67.45M | $6.20M | $-27.07M | $55.00K | 5.68% | 9.18% | -492.24× | Reported |
| 2021-09-30 | $3.97M | $65.14M | $6.50M | $-27.84M | $62.00K | 6.10% | 9.98% | -449.00× | Reported |
| 2021-06-30 | $3.82M | $62.01M | $6.25M | $-23.19M | $66.00K | 6.16% | 10.08% | -351.41× | Reported |
| 2021-03-31 | $3.64M | $59.59M | $6.35M | $-21.33M | $78.00K | 6.10% | 10.65% | -273.41× | Reported |
| 2020-12-31 | $3.73M | $59.26M | $6.94M | $-19.85M | $71.00K | 6.30% | 11.70% | -279.63× | Reported |
| 2020-09-30 | $3.88M | $56.90M | $6.86M | $-22.63M | $48.00K | 6.82% | 12.05% | -471.52× | Reported |
| 2020-06-30 | $4.04M | $54.77M | $6.97M | $-25.32M | $343.00K | 7.38% | 12.72% | -73.83× | Reported |
| 2020-03-31 | $4.17M | $50.59M | $7.02M | $-28.82M | (m) | 8.25% | 13.87% | (m) | (m) |
| 2019-12-31 | $4.42M | $46.29M | $7.17M | $-31.30M | $847.00K | 9.55% | 15.49% | -36.95× | Reported |
| 2019-09-30 | $4.56M | $42.27M | $7.46M | $-30.68M | $832.00K | 10.78% | 17.65% | -36.88× | Reported |
| 2019-06-30 | $4.86M | $38.34M | $7.09M | $-32.39M | $527.00K | 12.68% | 18.49% | -61.46× | Reported |
| 2019-03-31 | $5.21M | $35.04M | $7.14M | $-33.15M | (m) | 14.86% | 20.38% | (m) | (m) |
| 2018-12-31 | $5.48M | $31.56M | $6.37M | $-33.17M | $79.00K | 17.36% | 20.19% | -419.90× | Reported |
| 2018-09-30 | $5.66M | (m) | (m) | $-33.71M | $144.78K | (m) | (m) | -232.83× | Reported |
| 2018-06-30 | $5.35M | (m) | (m) | $-28.29M | $180.78K | (m) | (m) | -156.48× | Reported |
| 2018-03-31 | $4.78M | (m) | $5.54M | $-23.00M | $168.78K | (m) | (m) | -136.29× | Reported |
| 2017-12-30 | $4.01M | (m) | $4.60M | $-16.38M | $152.78K | (m) | (m) | -107.19× | Reported |
| 2017-09-30 | $3.09M | (m) | (m) | $-9.11M | $165.72K | (m) | (m) | -54.98× | Reported |
| 2017-07-01 | $2.82M | (m) | (m) | $-7.68M | $122.61K | (m) | (m) | -62.64× | Reported |
| 2017-04-01 | $2.72M | (m) | $1.19M | $-4.59M | $221.32K | (m) | (m) | -20.74× | Reported |
| 2016-12-31 | $2.52M | (m) | $1.19M | $-2.25M | $371.90K | (m) | (m) | -6.04× | Reported |
| 2016-10-01 | (m) | (m) | (m) | $-1.36M | $527.60K | (m) | (m) | -2.58× | Reported |
| 2016-07-02 | (m) | (m) | (m) | $-238.49K | $698.03K | (m) | (m) | -0.34× | Reported |
| 2016-04-02 | (m) | (m) | $1.59M | $-793.68K | $684.38K | (m) | (m) | -1.16× | Reported |
| 2016-01-02 | $891.60K | (m) | $1.98M | $-2.15M | $616.03K | (m) | (m) | -3.50× | Reported |
| 2015-10-03 | (m) | (m) | (m) | $-2.02M | $558.24K | (m) | (m) | -3.61× | Reported |
| 2015-07-04 | (m) | (m) | (m) | $-2.84M | $388.87K | (m) | (m) | -7.31× | Reported |
| 2015-04-04 | (m) | (m) | $2.63M | $-4.30M | $269.11K | (m) | (m) | -15.97× | Reported |
| 2015-01-03 | $514.00K | (m) | $2.86M | $-5.23M | $158.85K | (m) | (m) | -32.93× | Reported |
| 2014-09-27 | (m) | (m) | $2.64M | $-4.84M | $44.17K | (m) | (m) | -109.64× | Reported |
| 2014-06-28 | (m) | (m) | $2.54M | $-5.44M | $40.39K | (m) | (m) | -134.62× | Reported |
| 2014-03-29 | (m) | (m) | $1.89M | $-4.81M | $36.43K | (m) | (m) | -132.00× | Reported |
| 2013-12-28 | $134.00K | (m) | $1.29M | $-4.39M | $34.33K | (m) | (m) | -127.77× | Reported |
| 2013-09-28 | (m) | (m) | $1.57M | $-5.36M | $-27.18K | (m) | (m) | (m) | Reported |
| 2013-06-29 | (m) | (m) | $2.17M | $-2.76M | $-28.98K | (m) | (m) | (m) | Reported |
| 2013-03-30 | (m) | (m) | $2.99M | $-5.74M | $-28.53K | (m) | (m) | (m) | Reported |
| 2012-12-29 | $141.57K | (m) | $2.70M | $-11.64M | $-29.01K | (m) | (m) | (m) | Reported |
| 2012-09-29 | (m) | (m) | $2.69M | $-12.43M | $30.23K | (m) | (m) | -411.10× | Reported |
| 2012-07-02 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | (m) | $2.73M | $-13.29M | $30.89K | (m) | (m) | -430.40× | Reported |
| 2012-03-31 | (m) | (m) | $2.30M | $-11.14M | $31.53K | (m) | (m) | -353.31× | Reported |
| 2011-12-31 | (m) | (m) | $2.97M | $-7.86M | $32.14K | (m) | (m) | -244.67× | Reported |
| 2011-10-01 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-07-02 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-04-02 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-01-01 | (m) | (m) | $1.26M | $-2.02M | $36.07K | (m) | (m) | -55.93× | Reported |
| 2010-10-02 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-07-03 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| USANA HEALTH SCIENCES INC (USNA) | United States | $0.264B | -17.90 |
| FITLIFE BRANDS, INC. (FTLF) | United States | $0.087B | 16.59 |
| Canopy Growth Corp (CGC) | $0.395B | ||
| MANNATECH INC (MTEX) | United States | $0.014B | |
| NATURAL ALTERNATIVES INTERNATIONAL INC (NAII) | United States | $0.011B | -1.16 |
| Synergy CHC Corp. (SNYR) | United States | $0.001B | |
| Functional Brands Inc. (MEHA) | United States | $0.001B | |
| Tilray Brands, Inc. (TLRY) | United States | $0.554B | -5.97 |
| Cronos Group Inc. (CRON) | $1.223B | ||
| Definium Therapeutics, Inc. (DFTX) | United States | $4.931B | -17.87 |